Develops precision, non-radioactive small-molecule radioligand therapy (next‑generation BNCT) for breast cancer, including triple‑negative cases. Platform unlocks high‑value intracellular targets by combining pathway inhibition with neutron‑activated alpha-particle delivery for safer radiopharmaceutical treatment.